Inmune Bio (INMB) Enterprise Value (2017 - 2025)
Inmune Bio's Enterprise Value history spans 9 years, with the latest figure at -$27.7 million for Q3 2025.
- For Q3 2025, Enterprise Value rose 17.34% year-over-year to -$27.7 million; the TTM value through Sep 2025 reached -$27.7 million, up 17.34%, while the annual FY2024 figure was -$20.9 million, 41.64% up from the prior year.
- Enterprise Value for Q3 2025 was -$27.7 million at Inmune Bio, up from -$33.4 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$19.3 million in Q1 2025 and bottomed at -$84.5 million in Q3 2021.
- The 5-year median for Enterprise Value is -$39.5 million (2021), against an average of -$44.7 million.
- The largest annual shift saw Enterprise Value plummeted 720.6% in 2021 before it surged 49.02% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$74.8 million in 2021, then soared by 30.29% to -$52.2 million in 2022, then skyrocketed by 31.26% to -$35.8 million in 2023, then skyrocketed by 41.64% to -$20.9 million in 2024, then plummeted by 32.56% to -$27.7 million in 2025.
- Per Business Quant, the three most recent readings for INMB's Enterprise Value are -$27.7 million (Q3 2025), -$33.4 million (Q2 2025), and -$19.3 million (Q1 2025).